Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Core Viewpoint - Milestone Pharmaceuticals has received a Notice of Allowance for a new Method of Use patent for its lead investigational product, etripamil nasal spray (proposed trade name CARDAMYST), aimed at managing paroxysmal supraventricular tachycardia (PSVT) [1][2] Group 1: Patent and Intellectual Property - The patent covers the repeat dose regimen used in the RAPID Phase 3 study for CARDAMYST, which is part of the New Drug Application (NDA) currently under FDA review [2][4] - The Notice of Allowance potentially extends intellectual property protection for CARDAMYST in the U.S. until July 2042, providing an additional 6 years of protection [2][3] Group 2: Product Development and Commercialization - Etripamil is a novel calcium channel blocker nasal spray designed for self-administration, allowing patients to manage symptomatic episodes of PSVT and AFib-RVR without immediate medical oversight [5][6] - The NDA for CARDAMYST is under FDA review with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025, and commercial preparations are advancing for an anticipated launch in mid-2025 [4][6] Group 3: Company Overview - Milestone Pharmaceuticals focuses on developing innovative cardiovascular solutions to improve the lives of patients with complex heart conditions, emphasizing unmet patient needs and self-management [6]